Gamma-linolenic Acid Supplementation Study (GLASS)

Virta Health

Status: Completed

Conditions: Weight Trajectory

Treatments: Dietary Supplement: placebo; Dietary Supplement: gamma-linolenic acid

Study type: Interventional

Funder types: Industry

Identifiers

NCT04481724

2019-6

Details and patient eligibility

About

Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight loss maintenance in Virta Health patients.

Full description

The primary purpose of this research is to determine if GLA supplementation reduces weight regain over 24 months in Virta Health patients.

The secondary purpose is to determine the effect of GLA supplementation on diabetes-related outcomes.

Enrollment: 302 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to 18 yrs
• Patients referred to Virta Health by employers or insurers
• Weight loss greater than or equal to 7% of initial weight and current BMI > 25 kg/m2
• Willing to take 3 supplement capsules daily
• Able to understand study procedures and willing to provide informed consent
• English-speaking

Exclusion criteria

• Patients who are pregnant or lactating
• Patients who are taking or are prescribed orlistat

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

302 participants in 2 patient groups, including a placebo group

gamma-linolenic acid (GLA) supplementation

Experimental group

Description:

Sonova GLA safflower oil (840 mg GLA per day)

Treatment:

Dietary Supplement: gamma-linolenic acid

placebo control

Placebo Comparator group

Description:

1500 mg 'light' olive oil per day

Treatment:

Dietary Supplement: placebo